Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification

Trends in Endocrinology and Metabolism

Volumn 28, Issue 7, 2017, Pages 519-530

  Wang, Yajing ^a   Ma, Xin L ^a   Lau, Wayne Bond ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPOQ PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; HEART FAILURE; HEART INJURY; HUMAN; HYPOADIPONECTINEMIA; METABOLIC SYNDROME X; OBESITY; PHOSPHORYLATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; ANIMAL; CARDIAC MUSCLE; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; MYOCARDIUM; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION;

EID: 85018452193     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2017.03.004     Document Type: Review

References (83)

1. Scherer, P.E., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270 (1995), 26746–26749.
2. Hu, E., et al. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271 (1996), 10697–10703.
3. Maeda, K., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 425 (2012), 556–559.
4. Nakano, Y., et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 120 (1996), 803–812.
5. Al Khaldi, R., et al. Associations of TERC single nucleotide polymorphisms with human leukocyte telomere length and the risk of type 2 diabetes mellitus. PLoS One, 10, 2015, e0145721.
6. Liu, M., et al. Endoplasmic reticulum (ER) localization is critical for DsbA-L protein to suppress ER stress and adiponectin down-regulation in adipocytes. J. Biol. Chem. 290 (2015), 10143–10148.
7. Waki, H., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 278 (2003), 40352–40363.
8. Cnop, M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003), 459–469.
9. Lopez-Jaramillo, P., Ssa 04-3 leptin/adiponectin in cardiometabolic disease. J. Hypertens., 34(Suppl. 1), 2016, e7.
10. Martos-Moreno, G.A., Normative data for adiponectin, resistin, interleukin 6, and leptin/receptor ratio in a healthy Spanish pediatric population: relationship with sex steroids. Eur. J. Endocrinol. 155 (2006), 429–434.
11. Frederiksen, L., et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. Eur. J. Endocrinol. 166 (2012), 469–476.
12. Chang, C.S., et al. Role of adiponectin gene variants, adipokines and hydrometry-based percent body fat in metabolically healthy and abnormal obesity. Obes. Res. Clin. Pract., 2016, 10.1016/j.orcp.2016.05.003 Published online May 25, 2016.
13. Wang, Y., et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia–reperfusion injury. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E663–E670.
14. Kennedy, A., et al. Postprandial adiponectin and gelatinase response to a high-fat versus an isoenergetic low-fat meal in lean, healthy men. Nutrition 31 (2015), 863–870.
15. Yan, J., et al. Adiponectin-impaired adipocyte differentiation negatively regulates fat deposition in chicken. J. Anim. Physiol. Anim. Nutr. (Berl.) 98 (2014), 530–537.
16. Yamauchi, T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13 (2007), 332–339.
17. Nicolas, A., et al. T-cadherin gene variants are associated with type 2 diabetes and the fatty liver index in the French population. Diabetes Metab. 43 (2017), 33–39.
18. Liu, S.H., et al. Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition. Mol. Oncol. 9 (2015), 834–849.
19. Takemura, Y., et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest. 117 (2007), 375–386.
20. Ohashi, K., et al. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol. Cell. Biol. 29 (2009), 3487–3499.
21. Bell, S., Britton, A., The role of alcohol consumption in regulating circulating levels of adiponectin: a prospective cohort study. J. Clin. Endocrinol. Metab. 100 (2015), 2763–2768.
22. Ntzouvani, A., et al. Reduced circulating adiponectin levels are associated with the metabolic syndrome independently of obesity, lipid indices and serum insulin levels: a cross-sectional study. Lipids Health Dis., 15, 2016, 140.
23. Yaghootkar, H., et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62 (2013), 3589–3598.
24. Hashimoto, N., et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 55 (2006), 1653–1657.
25. Kojima, S., et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart, 89, 2003, 667.
26. Bittencourt, C., et al. Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography. Diabetol. Metab. Syndr., 6, 2014, 46.
27. Cheung, C.Y., et al. Adiponectin gene variants and the risk of coronary heart disease: a 16-year longitudinal study. Eur. J. Endocrinol. 171 (2014), 107–115.
28. Takemoto, F., et al. Plasma adiponectin: a predictor of coronary heart disease in hemodialysis patients – a Japanese prospective eight-year study. Nephron. Clin. Pract. 111 (2009), c12–c20.
29. Ohman-Hanson, R.A., Ethnic and sex differences in adiponectin: from childhood to adulthood. J. Clin. Endocrinol. Metab. 101 (2016), 4808–4815.
30. El-Shafey, E.M., Shalan, M., Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients. Ther. Apher. Dial. 18 (2014), 185–192.
31. Reinstadler, S.J., Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care 3 (2014), 10–17.
32. Hajer, G.R., et al. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am. Heart J., 154, 2007 750.e1–750.e7.
33. Buturak, A., et al. Elective percutaneous coronary intervention leads to significant changes in serum resistin, leptin, and adiponectin levels regardless of periprocedural myocardial injury: an observational study. Anatol. J. Cardiol. 16 (2016), 940–946.
34. Maruyama, S., et al. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J. Biol. Chem. 286 (2011), 32790–32800.
35. Tao, L., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115 (2007), 1408–1416.
36. Zhang, C., et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One, 8, 2013, e66382.
37. Zhang, Y., et al. Adiponectin inhibits oxidative/nitrative stress during myocardial ischemia and reperfusion via PKA signaling. Am. J. Physiol. Endocrinol. Metab. 305 (2013), E1436–E1443.
38. Migrenne, S., et al. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 (2009), R929–R935.
39. Tishinsky, J.M., et al. Insulin-sensitizing properties of adiponectin. Biochimie 94 (2012), 2131–2136.
40. Kuryszko, J., et al. Secretory function of adipose tissue. Pol. J. Vet. Sci. 19 (2016), 441–446.
41. Matczuk, J., et al. Insulin resistance and obesity affect lipid profile in the salivary glands. J. Diabetes Res., 2016, 2016, 8163474.
42. Putti, R., et al. Skeletal muscle mitochondrial bioenergetics and morphology in high fat diet induced obesity and insulin resistance: focus on dietary fat source. Front. Physiol., 6, 2015, 426.
43. Catalano, K.J., et al. Critical role of the mesenteric depot versus other intra-abdominal adipose depots in the development of insulin resistance in young rats. Diabetes 59 (2010), 1416–1423.
44. Mullen, K.L., et al. Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 (2009), R243–R251.
45. Bruce, C.R., et al. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 54 (2005), 3154–3160.
46. Li, R., et al. Reduced vascular responsiveness to adiponectin in hyperlipidemic rats − mechanisms and significance. J. Mol. Cell. Cardiol. 49 (2010), 508–515.
47. Zhao, L., et al. Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses. J. Physiol. 593 (2015), 4067–4079.
48. 2+-ATPase activity and inhibiting endoplasmic reticulum stress. J. Cardiovasc. Pharmacol. 62 (2013), 143–153.
49. Nduhirabandi, F., et al. Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity. J. Pineal Res. 57 (2014), 317–332.
50. Yi, W., et al. Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms. Antioxid. Redox Signal., 15, 2011 1779–1188.
51. Shibata, R., et al. Potential of adiponectin as a cardioprotective agent. Future Cardiol. 3 (2007), 647–656.
52. Ouchi, N., et al. Cardioprotection by adiponectin. Trends Cardiovasc. Med. 16 (2006), 141–146.
53. Koentges, C., et al. Myocardial mitochondrial dysfunction in mice lacking adiponectin receptor 1. Basic Res. Cardiol., 110, 2015, 37.
54. Durrani, S., et al. Relationship of adiponectin level with lipid profile in type-2 diabetic men with coronary heart disease. J. Ayub Med. Coll. Abbottabad 27 (2015), 32–35.
55. Antonopoulos, A.S., Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 64 (2015), 2207–2219.
56. Persson, J., et al. High plasma adiponectin concentration is associated with all-cause mortality in patients with carotid atherosclerosis. Atherosclerosis 225 (2012), 491–496.
57. Aso, Y., et al. Elevation of serum high molecular weight adiponectin in patients with type 2 diabetes and orthostatic hypotension: association with arterial stiffness and hypercoagulability. Diabet. Med. 29 (2012), 80–87.
58. Pischon, T., et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 219 (2011), 322–329.
59. Ortega Moreno, L., et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc. Diabetol., 15, 2016, 17.
60. Ortega Moreno, L., et al. The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: evidence of synergism with abdominal adiposity. Atherosclerosis 250 (2016), 23–29.
61. Laoutaris, I.D., et al. High plasma adiponectin is related to low functional capacity in patients with chronic heart failure. Int. J. Cardiol. 144 (2010), 230–231.
62. Sente, T., et al. Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J. Cachexia Sarcopenia Muscle 7 (2016), 261–274.
63. Sente, T., et al. Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity. BMC Cardiovasc. Disord., 16, 2016, 107.
64. Sente, T., et al. The evolving role of adiponectin as an additive biomarker in HFrEF. Heart Fail. Rev. 21 (2016), 753–769.
65. Keshvari, S., et al. Characterisation of the adiponectin receptors: the non-conserved N-terminal region of AdipoR2 prevents its expression at the cell-surface. Biochem. Biophys. Res. Commun. 432 (2013), 28–33.
66. Wu, Y.Y., et al. Effect of berberine on the ratio of high-molecular weight adiponectin to total adiponectin and adiponectin receptors expressions in high-fat diet fed rats. Chin. J. Integr. Med., 2016, 10.1007/s11655-016-2518-x Published online November 17, 2016.
67. Kim, J.C., The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats. J. Exerc. Nutrition Biochem. 20 (2016), 42–50.
68. Landrier, J.F., et al. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue. FASEB J. 31 (2016), 203–211.
69. Francisco, C., et al. Can adiponectin help us to target diastolic dysfunction?. Cardiovasc. Drugs Ther. 30 (2016), 635–644.
70. Loncar, G., et al. Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur. J. Intern. Med. 24 (2013), 818–823.
71. Kreth, S., et al. MicroRNA-150 inhibits expression of adiponectin receptor 2 and is a potential therapeutic target in patients with chronic heart failure. J. Heart Lung Transplant. 33 (2014), 252–260.
72. Fang, X., et al. Hyperglycemia- and hyperinsulinemia-induced alteration of adiponectin receptor expression and adiponectin effects in L6 myoblasts. J. Mol. Endocrinol. 35 (2005), 465–476.
73. Kim, H.K., et al. The expression of adiponectin receptor is altered in mild and moderate/severe persistent allergic nasal mucosa. Am. J. Rhinol. Allergy 25 (2011), 318–322.
74. Martinez Cantarin, M.P., et al. Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrol. Dial. Transplant. 29 (2014), 2268–2277.
75. Wang, Y., et al. G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart. Circulation 131 (2015), 1392–1404.
76. 2-adrenoceptor signaling is dictated by GRK2 phosphorylation in cardiomyocytes. J. Biol. Chem. 283 (2008), 1799–1807.
77. Ding, Q., et al. Endocytosis of adiponectin receptor 1 through a clathrin- and Rab5-dependent pathway. Cell Res. 19 (2009), 317–327.
78. Wang, Y., et al. Adiponectin inhibits tumor necrosis factor-alpha-induced vascular inflammatory response via caveolin-mediated ceramidase recruitment and activation. Circ. Res. 114 (2014), 792–805.
79. Wang, Y., et al. Essential role of caveolin-3 in adiponectin signalsome formation and adiponectin cardioprotection. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 934–942.
80. Mao, X., et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 8 (2006), 516–523.
81. Ouchi, N., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102 (2000), 1296–1301.
82. Tang, Y.T., et al. PAQR proteins: a novel membrane receptor family defined by an ancient 7-transmembrane pass motif. J. Mol. Evol. 61 (2005), 372–380.
83. Gesty-Palmer, D., et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281 (2006), 10856–10864.